Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma

Cancer

Volumn 89, Issue 1, 2000, Pages 104-115

  Goldenberg, David M ^a   Abdel Nabi, Hani ^b   Sullivan, Cynthia L ^c   Serafini, Aldo ^d   Seldin, David ^e   Barron, Bruce ^f   Lamki, Lamk ^f   Line, Bruce ^g   Wegener, William A ^c  

^a GARDEN STATE CANCER CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c IMMUNOMEDICS INC   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g ALBANY MEDICAL CENTER   (United States)

Author keywords

Antibodies; Arcitumomab; Breast carcinoma; Carcinoembryonic antigen; CEA Scan; Diagnosis; Imaging; Immunoscintigraphy; Mammography

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADULT; ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTICENTER STUDY; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CARCINOMA, PAPILLARY; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; RADIOIMMUNODETECTION; SENSITIVITY AND SPECIFICITY; TECHNETIUM;

EID: 0034234654     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000701)89:1<104::AID-CNCR15>3.0.CO;2-E     Document Type: Article

References (79)

1. Glass AG, Hoover RN. Rising incidence of breast cancer: relationship to stage and receptor status. J Natl Cancer Inst 1990;82:693-6.
2. Miller BA, Feuer EJ, Hankey BF. Recent incidence trends for breast cancer in women and the relevance of early detection: an update. CA Cancer J Clin 1993;43:27-41.
3. Sondik EJ. Breast cancer trends. Incidence, mortality and survival. Cancer 1994;74:995-9.
4. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892-7.
5. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (1). N Engl J Med 1992;327:319-28.
6. Shapiro S. Screening: assessment of current studies. Cancer 1994;74:231-8.
7. Smart CR, Hendrick RE, Rutledge JH III, Smith RA. Benefit of mammography screening in women ages 40-49 years: current evidence from randomized controlled trials. Cancer 1995;75:1619-26. Correction: Cancer 1995;75:2788.
8. Tabar L, Fagerberg G, Chen H-H, Duffy SW, Smart CR, Gad A, et al. Efficacy of breast cancer screening by age: new results from the Swedish Two-County Trial. Cancer 1995;75: 997-1003.
9. Hendrick RE, Smith RA, Rutledge JH, Smart CR. Benefit of screening mammography in women ages 40-49: a new meta-analysis of randomized controlled trials. Monogr Natl Cancer Inst 1997;22:87-92.
10. Feig SA. Decreased breast cancer mortality through mammographic screening. Radiology 1988;167:659-65.
11. Haffry BG, Lee C, Philpotts L, Horvath L, Ward B, McKhann C, et al. Prognostic significance of mammographic detection in a cohort of conservatively treated breast cancer patients. Cancer J Sci Am 1998;4:35-40.
12. Kopans DB. The mammography screening controversy. Cancer J Sci Am 1998;4:22-4.
13. Feig SA. Role and evaluation of mammography and other imaging methods for breast cancer detection, diagnosis, and staging. Semin Nucl Med 1999;29:3-15.
14. Homer MJ. Nonpalpable breast abnormalities: a realistic view of the accuracy of mammography in detecting malignancies. Radiology 1984;153:831-2.
15. Albert MP, Sachsse E, Coe NP, Page DW, Reed WP. Correlation between mammography and the pathology of nonpalpable breast lesions. J Surg Oncol 1990;44:44-6.
16. Symmonds RE Jr., Roberts JW. Management of nonpalpable breast abnormalities. Am Surg 1987;205:520-8.
17. Perdue P, Page D, Nellestein M, Salem C, Galbo C, Ghosh B. Early detection of breast carcinoma: a comparison of palpable and nonpalpable lesions. Surgery 1992;111:656-9.
18. Miller RS, Adelman RW, Espinosa MH, Dorman SA, Smith DH. The early detection of nonpalpable breast carcinoma with needle localization. Experience with 500 patients in a community hospital. Am Surg 1992;58:193-8.
19. Opie H, Estes NC, Jewell WR, Chang CH, Thomas JA, Estes MA. Breast biopsy for nonpalpable lesions: a worthwhile endeavor? Am Surg 1993;59:490-3.
20. Knutzen AM, Gisvold JJ. Likelihood of malignant disease for various categories of mammographically detected, nonpalpable breast lesions. Mayo Clin Proc 1993;68:454-60.
21. Schwartz GF, Carter DL, Conant EF, Gannon FH, Finkel GC, Feig SA. Mammographically detected breast cancer. Nonpalpable is not a synonym for inconsequential. Cancer 1994; 73:1660-5.
22. Sailors DM, Crabtree JD, Land RL, Rose WB, Burns RP, Barker DE. Needle localization for nonpalpable lesions. Am Surg 1994;60:186-9.
23. Perdue PW, Galbo C, Ghosh BC. Stratification of palpable and nonpalpable breast cancer by method of detection and age. Ann Surg Oncol 1995;2:512-5.
24. Rosenberg RD, Lando JF, Hunt WC, Darling RR, Williamson MR, Linver MN, et al. The New Mexico Mammography Project. Screening mammography performance in Albuquerque, New Mexico, 1991 to 1993. Cancer 1996;78:1731-9.
25. Coveney EC, Geraaghty JG, O'Laoide R, Hourihane JB, O'Higgins NJ. Reasons underling negative mammography in patients with palpable breast cancer. Clin Radiol 1994;49: 123-5.
26. Elmore JG, Wells CK, Lee CH, Howard DH, Feinstein AR. Variability in radiologists' interpretations of mammograms. N Engl J Med 1994;331:1493-9.
27. Beam CA, Layde PM, Sullivan DC. Variability in the interpretation of screening mammography by US radiologists. Findings from a national sample. Arch Intern Med 1996;156: 209-13.
28. Elmore JG, Wells CK, Howard DH. Does diagnostic accuracy in mammography depend on radiologists' experience? J Womens Health 1998;7:443-9.
29. Jones TL. The worst list. Breast cancer now leading source of medical malpractice claims. Tex Med 1996;92:34-6.
30. Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi. Eur J Nucl Med 1994;21:357-62.
31. Adler DD, Wahl RL. New methods for imaging the breast: techniques, findings, and potential. AJR Am J Roentgenol 1995;164:19-30.
32. Sabel M, Aichinger H. Recent developments in breast imaging. Phys Med Biol 1996;41:315-68.
33. Bassett LW. Imaging the breast. In: Holland JF, Frei E III, Bast RC Jr., Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer medicine. 4th ed. Baltimore: Williams & Wilkins, 1997;589-96.
34. Khalkhali I, Cutrone JA, Mena I. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196:421-6.
35. Scopinaro F, Schillaci O, Ussof W, Nordling K, Capoferro R, De Vincentis G, et al. A three center study on the diagnostic accuracy of 99mTc-MIBI scintimammography. Anticancer Res 1997;17:1631-4.
36. Palmedo H, Biersack HJ, Lastoria S, Maublant J, Prats E, Stegner HE, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 1998;25:375-85.
37. Tiling R, Khalkhali I, Sommer H, Linke R, Moser R, Willemsen F, et al. Limited value of scintimammography and contrast-enhanced MRI in the evaluation of microcalcification detected by mammography. Nucl Med Commun 1998;19:55-62.
38. Salvatore M, Del Vecchio S. Dynamic imaging: scintimammography. Eur J Radiol 1998;(Suppl 2):S259-64.
39. Taillefer R. The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med 1999;29:16-40.
40. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR Jr., et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384-8.
41. Goldenberg DM, Kim EE, DeLand FH, Bennett SJ, Primus FJ. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 1980;40:2984-92.
42. Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992;33:803-14.
43. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:467-81
44. Gold P, Goldenberg NA. The carcinoembryonic antigen (CEA): past, present, and future. McGill J Med 1997;3:46-66.
45. Heyderman E, Neville M. A shorter immunoperoxidase technique for the demonstration of carcinoembryonic antigen and other cell products. J Clin Pathol 1977;30:138-40.
46. Wahren B, Lindbrink E, Wallgren A, Eneroth P, Zajicek J. Carcinoembryonic antigen and other tumor markers in tissue and serum or plasma of patients with primary mammary carcinoma. Cancer 1978;42:1870-8.
47. Walker RA. Demonstration of carcinoembryonic antigen in human breast carcinomas by the immunoperoxidase technique. J Clin Pathol 1980;33:356-60.
48. Kleist von S, Wittekind C, Sandritter W, Gropp H. CEA positivity in sera and breast tumor tissues obtained from the same patients. Pathol Res Pract 1982;173:390-401.
49. Böcker W, Schweikhart G, Pollow K, Kreienberg R, Klaubert A, Schroder S, et al. Immunohistochemical demonstration of carcinoembryonic antigen (CEA) in 120 mammary carcinomas and its correlation with tumor type, grading, staging plasma-CEA, and biochemical receptor status. Pathol Res Pract 1985;180:490-7.
50. Chung JK, Jang JJ, Lee DS, Lee MC, Koh CS. Tumor concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography. J Nucl Med 1994;35:1499-505.
51. Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 1994;74:1575-83.
52. Schmitt FC, Andrade L. Spectrum of carcinoembryonic antigen immunoreactivity from isolated ductal hyperplasias to atypical hyperplasias associated with infiltrating ductal breast cancer. J Clin Pathol 1995;48:53-6.
53. Imayama S, Mori M, Ueo H, Nanbara S, Adachi Y, Mimori K, et al. Presence of elevated carcinoembryonic antigen on absorbent disks applied to nipple area of breast carcinoma patients. Cancer 1996;78:1229-34.
54. Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995;55:3417-20.
55. Salmon MA, Jurdan M, Brasseur F, Feyens AF, Symann M. CEA RT-PCR is a sensitive method to detect breast tumor cells in peripheral blood and in progenitor cell collections prior to and following CD34+ cell selection [abstract]. Blood 1997;90(Suppl):354b.
56. Kim EE, Corgan RL, Casper S, Primus FJ, Spremulli E, Estes N, et al. Axillary lymphoscintigraphy in radioimmunodetection of carcinoembryonic antigen in breast cancer. J Nucl Med 1979;20:1243-50.
57. 99mTc-labeled monoclonal antibody (BW431/26) reacting with carcinoembryonic antigen in breast cancer. Cancer Res 1990; 50:949-54.
58. Thor AD, Edgerton SM. Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications. Semin Nucl Med 1989;19:295-308.
59. Lind P, Smola MG, Lechner P, Ratschek M, Klima G, Koltringer P, et al. The immunoscintigraphic use of Tc-99m-labeled monoclonal anti-CEA antibodies (BW431/26) in patients with suspected primary, recurrent and metastatic breast cancer. Int J Cancer 1991;47:865-9.
60. Nabi HA. Antibody imaging in breast cancer. Semin Nucl Med 1997;27:30-9.
61. Baum RP, Brümmendorf TH. Radioimmunolocalization of primary and metastataic breast cancer. Q J Nucl Med 1998; 42:33-42.
62. Goldenberg DM, Nabi HA. Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med 1999;29:41-8.
63. Hansen HJ, Sullivan CL, Sharkey RM, Goldenberg DM. HAMA interference with murine monoclonal antibody-based immunoassays. J Clin Immunoassay 1993;16:294-9.
64. 99mTc-labeling kit for antibody imaging. Cancer Res 1990;50:794s-8s.
65. American College of Radiology. Breast imaging reporting and data system (BI-RADS) 3rd ed. Reston, VA: American College of Radiology, 1998.
66. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Aorrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-65.
67. Heywant-Kobrunner SH, Scheer I, Dershaw DD. Diagnostic breast imaging, mammography, sonography, magnetic resonance imaging and interventional procedures. Chapter 9. New York: Thieme Stutgart, 1997.
68. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Likelihood ratios for modern screening mammography. Risk of breast cancer on age and mammographic interpretation. JAMA 1966;276:39-43.
69. Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991;44:763-70.
70. Simel DL, Feussner JR, Delong ER, Matchar DM. Intermediate, indeterminate, and uninterpretable diagnostic test results. Med Decis Making 1987;7:107-14.
71. American Joint Committee on Cancer. Manual for staging of cancer. Philadelphia: J.B. Lippincott, 1992
72. Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR Am J Roentgenol 1995;165:1373-7.
73. Centers for Disease Control and Prevention. Cancer screening behaviors among U.S. women: breast cancer, 1987-1989, and cervical cancer, 1988-1989. MMWR Morb Mortal Wkly Rep 1992;41(SS-2):17-34.
74. Beam CA, Layde PM, Sullivan DC. Variability in the interpretation of screening mammograms by US radiologists. Findings from a national sample. Arch Intern Med 1996;156: 209-13.
75. McCarty BD, Yood MU, Boohaker EA, Ward RE, Rebner M, Johnson CC. Inadequate follow-up of abnormal mammograms. Am J Prev Med 1996;12:282-8.
76. Moffat F, Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley ES, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment inpatients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. J Clin Oncol 1996;14:2295-305.
77. Wegener WA, Petrelli N, Serafini A, Goldenberg DM. Safety and efficacy of Arcitumomab imaging in colorectal cancer following repeat administrations. J Nucl Med. 2000;41:1016-20.
78. Tolmos J, Cutrone JA, Wang B, Vargas HI, Stuntz M, Mishkin FS, et al. Scintimammographic analysis of nonpalpable breast lesions previously identified by conventional mammography. J Natl Cancer Inst 1998;90:846-9.
79. Cutrone JA, Yospur LS, Khalkhali I, Tolmos J, Devito A, Diggles L, et al. Immunohistologic assessment of technetium-99m-MIBI uptake in benign and malignant breast lesions. J Nucl Med 1998;39:449-53.